Stay updated on Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page.
Latest updates to the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedLocations section expanded with numerous new sites across the US and other countries, and several previously listed locations were removed. The page revision updated from v3.3.2 to v3.3.3.SummaryDifference2%
- Check24 days agoNo Change Detected
- Check39 days agoChange DetectedNew study sites in Chiba, Sapporo, and Ishikawa (with local institution IDs) were added and several centers were removed. Revision 3.3.2 and updated milestone dates (e.g., 2025-11-21, 2026-02-27, 2031-02-27) accompany these changes.SummaryDifference0.7%
- Check46 days agoChange DetectedRemoved the notice about government funding and NIH operating status from the page; this does not affect the study details, eligibility criteria, or results information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check53 days agoChange DetectedAdded two Tainan locations (Tainan, Taiwan, 736 and Tainan, TNN, Taiwan, 704) and removed two Tainan City entries (Tainan City, Taiwan, 736; Tainan City, Taiwan, 704).SummaryDifference0.0%
- Check68 days agoChange DetectedThe page changes appear limited to cosmetic layout updates and do not modify core study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check90 days agoChange DetectedRelease v3.2.0 is introduced with a government-funding notice and updated operating status information; prior v3.1.0 is removed.SummaryDifference3%
Stay in the know with updates to Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page.